Organogenesis Holdings (ORGO) Debt/Equity Ratio: History & Chart

Organogenesis Holdings Inc.(ORGO)

Drug Manufacturers - Specialty & Generic · Canton, MA

$1.34+0.05 (+3.88%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Canton, MA

854 employees

organogenesis.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Gary S. Gillheeney

View full financials

ORGO Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.23

DEBT TO EQUITY RATIO AVG TTM

0.19

DEBT TO EQUITY RATIO AVG 3Y

0.29

DEBT TO EQUITY RATIO AVG 5Y

0.38

DEBT TO EQUITY RATIO AVG 10Y

0.32

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+23.20%

CURRENT VS 3Y AVG

-19.51%

CURRENT VS 5Y AVG

-39.16%

CURRENT VS 10Y AVG

-27.49%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.11

median of 774 covered companies

CURRENT VS SECTOR MEDIAN

+111.24%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Organogenesis Holdings Inc. (ORGO)	$172.42M	0.23	0.19	0.29	0.38
Precision BioSciences, Inc. (DTIL)vs ›	$171.13M	0.62	0.42	0.73	0.54
ProQR Therapeutics N.V. (PRQR)vs ›	$173.76M	0.17	0.23	0.32	0.40
Yarrow Bioscience Inc (YARW)vs ›	$174.27M	0.00	0.00	0.00	0.16
Journey Medical Corporation (DERM)vs ›	$169.53M	0.80	1.04	1.07	0.91
MediWound Ltd. (MDWD)vs ›	$168.92M	0.27	0.21	0.17	0.19
Cue Biopharma, Inc. (CUE)vs ›	$168.10M	3.81	0.34	0.34	0.27
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$179.26M	0.00	0.00	0.08	0.07
OptimizeRx Corp. (OPRX)vs ›	$165.32M	0.15	0.24	0.19	0.13
Nkarta, Inc. (NKTX)vs ›	$165.27M	0.30	0.22	0.24	0.18

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Organogenesis Holdings Inc. (ORGO)

$172.42M

0.23

0.19

0.29

0.38

Precision BioSciences, Inc. (DTIL)vs ›

$171.13M

0.62

0.42

0.73

0.54

ProQR Therapeutics N.V. (PRQR)vs ›

$173.76M

0.17

0.23

0.32

0.40

Yarrow Bioscience Inc (YARW)vs ›

$174.27M

0.00

0.16

Journey Medical Corporation (DERM)vs ›

$169.53M

0.80

1.04

1.07

0.91

MediWound Ltd. (MDWD)vs ›

$168.92M

0.27

0.21

0.17

0.19

Cue Biopharma, Inc. (CUE)vs ›

$168.10M

3.81

0.34

0.27

Oramed Pharmaceuticals Inc. (ORMP)vs ›

$179.26M

0.00

0.08

0.07

OptimizeRx Corp. (OPRX)vs ›

$165.32M

0.15

0.24

0.19

0.13

Nkarta, Inc. (NKTX)vs ›

$165.27M

0.30

0.22

0.24

0.18

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Organogenesis Holdings Inc. (ORGO)?

The debt to equity ratio for ORGO stock is 0.23.

Is Organogenesis Holdings Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.23 is 39% below its 5-year average of 0.38, near the low end of its 5-year range (0.11–0.63).

What is the TTM average debt to equity ratio for Organogenesis Holdings Inc. (ORGO)?

The TTM average debt to equity ratio for ORGO stock is 0.19.

What is the 3Y average debt to equity ratio for Organogenesis Holdings Inc. (ORGO)?

The 3Y average debt to equity ratio for ORGO stock is 0.29.

What is the 5Y average debt to equity ratio for Organogenesis Holdings Inc. (ORGO)?

The 5Y average debt to equity ratio for ORGO stock is 0.38.

What is the 10Y average debt to equity ratio for Organogenesis Holdings Inc. (ORGO)?

The 10Y average debt to equity ratio for ORGO stock is 0.32.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.23
2026-03-31	0.19
2025-12-31	0.31
2025-09-30	0.11
2025-06-30	0.11
2025-03-31	0.12
2024-12-31	0.11
2024-09-30	0.39
2024-06-30	0.43
2024-03-31	0.43
2023-12-31	0.43
2023-09-30	0.45
2023-06-30	0.46
2023-03-31	0.47
2022-12-31	0.47
2022-09-30	0.51
2022-06-30	0.52
2022-03-31	0.54
2021-12-31	0.55
2021-09-30	0.59
2021-06-30	0.63
2021-03-31	0.63
2020-12-31	0.60
2020-09-30	1.75
2020-06-30	3.23
2020-03-31	2.73
2019-12-31	1.81
2019-09-30	7.87
2019-06-30	3.89
2019-03-31	2.70
2018-12-31	1.26
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.06
2017-09-30	0.00
2017-06-30	0.00
2017-03-31	0.00
2016-12-31	0.00
2016-09-30	0.00
2016-06-30	-10.79
2016-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.23

2026-03-31

0.19

2025-12-31

0.31

2025-09-30

0.11

2025-06-30

0.11

2025-03-31

0.12

2024-12-31

0.11

2024-09-30

0.39

2024-06-30

0.43

2024-03-31

0.43

2023-12-31

0.43

2023-09-30

0.45

2023-06-30

0.46

2023-03-31

0.47

2022-12-31

0.47

2022-09-30

0.51

2022-06-30

0.52

2022-03-31

0.54

2021-12-31

0.55

2021-09-30

0.59

2021-06-30

0.63

2021-03-31

0.63

2020-12-31

0.60

2020-09-30

1.75

2020-06-30

3.23

2020-03-31

2.73

2019-12-31

1.81

2019-09-30

7.87

2019-06-30

3.89

2019-03-31

2.70

2018-12-31

1.26

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.06

2017-09-30

0.00

2017-06-30

0.00

2017-03-31

0.00

2016-12-31

0.00

2016-09-30

0.00

2016-06-30

-10.79

2016-03-31

0.00

Debt to Equity Ratio: 0.23

ORGO Debt to Equity Ratio

ORGO Average Debt to Equity Ratio Chart

ORGO Current vs Average Debt to Equity Ratio Chart

ORGO Debt to Equity Ratio Metrics

ORGO Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

ORGO Debt to Equity Ratio History

Related Metrics